SUBSCRIBE
SUBSCRIBE
News   Drug Development

Celgene’s (JOBS) Revlimid Drug Meets Goal in CALGB Study

December 18, 2009 | 
1 min read
Bookmark and Share

Reuters -- Celgene Corp said on Friday that initial results from a trial of its cancer drug Revlimid showed it delayed disease progression in patients with multiple myeloma who had undergone a stem cell transplant.
Clinical research Postmarket research
MORE ON THIS TOPIC
Contemporary art collage of human hands holding a arrow pointing up, graphs and diagrams. Concept of profit, making money, business. Copy space.
Weight loss
Metsera Shares Rise as Monthly Weight Loss Injection Shaves Over 8% Body Weight at 36 Weeks
June 9, 2025
 · 
3 min read
 · 
Tristan Manalac
World kidney day. Human hands holding healthy kidney shape made from paper on light blue background.
Rare diseases
Apellis, Sobi See Potential ‘Best-in-Class’ Efficacy for Empaveli in Rare Kidney Diseases
June 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Sanofi's Distribution Center in Quebec, Canada
Immunology and inflammation
Sanofi, Regeneron Tout Dupixent’s Effectiveness in Patients With Darker Skin Tone
June 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Abstract futuristic glowing with yellow light round sphere space star. Big data visualization. Abstract motion background shining particles, stars, magic dust flow in space. 3D rendering
Radiopharmaceuticals
Perspective Therapeutics Brings Energy to the Radiopharma World
June 6, 2025
 · 
2 min read
 · 
Dan Samorodnitsky